Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 493.5 INR 4.29% Market Closed
Market Cap: 203.4B INR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+3%
Revenue
Forecast
+25%
Operating Income
Forecast
+30%
Net Income
Forecast
+24%

Wall Street
Price Targets

ERIS Price Targets Summary
Eris Lifesciences Ltd

Wall Street analysts forecast ERIS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ERIS is 1 531.66 INR with a low forecast of 1 282.7 INR and a high forecast of 1 785 INR.

ERIS Lowest Forecast
Wall Street Target
1 282.7 INR
14% Downside
ERIS Average Forecast
Wall Street Target
1 531.66 INR
3% Upside
ERIS Highest Forecast
Wall Street Target
1 785 INR
20% Upside
Lowest
Price Target
1 282.7 INR
14% Downside
Average
Price Target
1 531.66 INR
3% Upside
Highest
Price Target
1 785 INR
20% Upside
Eris Lifesciences Ltd Competitors:
Price Targets
AXSM
Axsome Therapeutics Inc
61% Upside
K
4521
Kaken Pharmaceutical Co Ltd
21% Upside
600535
Tasly Pharmaceutical Group Co Ltd
14% Upside
T
1666
Tong Ren Tang Technologies Co Ltd
36% Upside
AXSM
Axsome Therapeutics Inc
61% Upside
K
4521
Kaken Pharmaceutical Co Ltd
21% Upside
600535
Tasly Pharmaceutical Group Co Ltd
14% Upside
T
1666
Tong Ren Tang Technologies Co Ltd
36% Upside
ROVI
Laboratorios Farmaceuticos ROVI SA
54% Upside
XERS
Xeris Biopharma Holdings Inc
35% Upside
ARVN
Arvinas Inc
321% Upside
C
300765
CSPC Innovation Pharmaceutical Co Ltd
16% Upside

Revenue
Forecast

Revenue Estimate
Eris Lifesciences Ltd

For the last 8 years the compound annual growth rate for Eris Lifesciences Ltd's revenue is 16%. The projected CAGR for the next 3 years is 25%.

16%
Past Growth
25%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Eris Lifesciences Ltd

For the last 8 years the compound annual growth rate for Eris Lifesciences Ltd's operating income is 16%. The projected CAGR for the next 3 years is 30%.

16%
Past Growth
30%
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Eris Lifesciences Ltd

For the last 8 years the compound annual growth rate for Eris Lifesciences Ltd's net income is 17%. The projected CAGR for the next 3 years is 24%.

17%
Past Growth
24%
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

See Also

Summary
ERIS intrinsic value, competitors valuation, and company profile.
DCF Valuation
ERIS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ERIS stock valuation using valuation multiples.
Wall Street Estimates
ERIS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ERIS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ERIS's stock price target?
Price Target
1 531.66 INR

According to Wall Street analysts, the average 1-year price target for ERIS is 1 531.66 INR with a low forecast of 1 282.7 INR and a high forecast of 1 785 INR.

What is Eris Lifesciences Ltd's Revenue forecast?
Projected CAGR
25%

For the last 8 years the compound annual growth rate for Eris Lifesciences Ltd's revenue is 16%. The projected CAGR for the next 3 years is 25%.

What is Eris Lifesciences Ltd's Operating Income forecast?
Projected CAGR
30%

For the last 8 years the compound annual growth rate for Eris Lifesciences Ltd's operating income is 16%. The projected CAGR for the next 3 years is 30%.

What is Eris Lifesciences Ltd's Net Income forecast?
Projected CAGR
24%

For the last 8 years the compound annual growth rate for Eris Lifesciences Ltd's net income is 17%. The projected CAGR for the next 3 years is 24%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 252,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.